Daily non-political popular news in brief.

Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation

Data presented today at the European League Against Rheumatism Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis who received Remicade over two years experienced significant improvement in spinal mobility. In addition, Remicade-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging.

Read more »

Keywords: remicade, data, ankylosing, spondylitis, show, improvement, spinal, mobility, inflammation, spondyliti

« Previous | Next »

Similar news on "Remicade data in ankylosing spondylitis show improvement in spinal mobility and spinal inflammation":

1. Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
   11-13-2006 · EurekAlert!
   Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.
   Similar news · Read more »
   
2. REMICADE-treated patients experienced substantial improvement in psoriasis in critical body regions
   02-01-2008 · EurekAlert!
   Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe psoriasis receiving REMICADE achieved a consistently high level of skin clearance in the head, trunk, lower and upper extremities as measured by the Psoriasis Area Severity Index. At week 10 of the analysis, 71 percent and 79 percent of patients receiving REMICADE 3 mg/kg or 5 mg/kg, respectively, achieved a at least a 75 percent improvement in psoriasis.
   Similar news · Read more »
   
3. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
4. 1-year results of bronchial thermoplasty in refractory asthma
   02-11-2008 · EurekAlert!
   Data from the Research in Severe Asthma trial of bronchial thermoplasty published in the American Journal of Respiratory and Critical Care Medicine show that patients experienced long term improvement in pulmonary function, improved quality of life and asthma control, and a reduction in rescue medication use for patients treated with bronchial thermoplasty.
   Similar news · Read more »
   
5. Long-term ulcerative colitis study shows Remicade responders maintained improvement
   05-23-2007 · EurekAlert!
   Findings presented today at Digestive Disease Week 2007, from long-term extensions of the ACT trials show that subjects with moderately to severely active ulcerative colitis who had responded to REMICADE in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.
   Similar news · Read more »
   
6. Home improvement warning -- Ladder-related injuries increasing in the US
   05-08-2007 · EurekAlert!
   Falls from ladders can result in serious injury and affect people of all ages. The general public is at risk for ladder injuries, yet receives little, if any instruction on ladder use and safety. A new study, the first to use national data to comprehensively examine nonfatal ladder-related injuries, show the number of injuries increased by more than 50 percent during the 16-year study period.
   Similar news · Read more »
   
7. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
   02-02-2007 · EurekAlert!
   Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving Remicade (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).
   Similar news · Read more »
   
8. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
   10-15-2007 · EurekAlert!
   REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis. According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials, there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo.
   Similar news · Read more »
   
9. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
   10-23-2006 · EurekAlert!
   Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
   Similar news · Read more »
   
10. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
    09-10-2007 · EurekAlert!
    Accentia Biopharmaceuticals announces evidence that most, if not all cases of chronic sinusitis, are due to a fungal-induced inflammation as originally proposed by investigators at the Mayo Clinic. The data were collected as part of the company's ongoing pivotal phase 3 clinical trial for its lead pharmaceutical product, SinuNase™, an intranasal formulation of the antifungal amphotericin B 0.01 percent suspension.
    Similar news · Read more »